ダウンロード数: 313

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
29_0365.pdf251.52 kBAdobe PDF見る/開く
タイトル: 前立腺肥大症に対する脂質代謝改善剤モリステロールの効果
その他のタイトル: Effect of Moristerol (anti-cholesterolemic agent) on benign prostatic hypertrophy
著者: 田島, 惇  KAKEN_name
大見, 嘉郎  KAKEN_name
阿曽, 佳郎  KAKEN_name
太田, 信隆  KAKEN_name
牛山, 知己  KAKEN_name
畑, 昌宏  KAKEN_name
藤井, 一彦  KAKEN_name
増田, 宏昭  KAKEN_name
著者名の別形: Tajima, Atsushi
Ohmi, Yoshio
Aso, Yoshio
Ohta, Nobutaka
Ushiyama, Tomomi
Hata, Masahiro
Fujii, Kazuhiko
Masuda, Hiroaki
キーワード: Anticholesteremic Agents/therapeutic use
Drug Evaluation
Humans
Lipids/blood
Male
Phytosterols/therapeutic use
Prostatic Hyperplasia/blood/drug therapy
発行日: Mar-1983
出版者: 泌尿器科紀要刊行会
誌名: 泌尿器科紀要
巻: 29
号: 3
開始ページ: 365
終了ページ: 369
抄録: Moristerol was orally administered in 20 cases of benign prostatic hypertrophy. One capsule of Moristerol contained 200 mg of soysterol . In all the cases, 9 capsules of Moristerol were given per day in three divided doses for 6 weeks. Clinical improvement was observed in 11 of the 20 cases (55%). It consisted mainly of subjective complaints such as improvement of dysuria, narrow and weak urinary stream and feeling of incomplete voiding. As objective findings, a statistically significant decrease of residual urine volume was noted after treatment, although shrinkage of the enlarged prostate was not clear upon palpation or roentgenography. In addition to the improvement of symptoms, serum lipid peroxide which might be considered to be a provocative cause of benign prostatic hypertrophy, was also significantly decreased by Moristerol administration. No marked side effects were seen in this study.
URI: http://hdl.handle.net/2433/120129
PubMed ID: 6203383
出現コレクション:Vol.29 No.3

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。